CR20140226A - Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes - Google Patents
Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunesInfo
- Publication number
- CR20140226A CR20140226A CR20140226A CR20140226A CR20140226A CR 20140226 A CR20140226 A CR 20140226A CR 20140226 A CR20140226 A CR 20140226A CR 20140226 A CR20140226 A CR 20140226A CR 20140226 A CR20140226 A CR 20140226A
- Authority
- CR
- Costa Rica
- Prior art keywords
- immune
- autoimmune diseases
- treat cancer
- inductive agents
- apoptosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547165P | 2011-10-14 | 2011-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20140226A true CR20140226A (es) | 2014-07-17 |
Family
ID=48086389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20140226A CR20140226A (es) | 2011-10-14 | 2014-05-14 | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes |
Country Status (5)
| Country | Link |
|---|---|
| US (6) | US8940737B2 (es) |
| CN (1) | CN103958508B (es) |
| CR (1) | CR20140226A (es) |
| GT (1) | GT201400066A (es) |
| UA (1) | UA112326C2 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| CN103987711B (zh) | 2011-10-14 | 2016-08-24 | 艾伯维公司 | 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物 |
| US8940737B2 (en) | 2011-10-14 | 2015-01-27 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| KR20140119023A (ko) | 2011-12-13 | 2014-10-08 | 버크 인스티튜트 포 리서치 온 에이징 | 의료 요법을 개선하는 방법 |
| WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| CN106163557B (zh) | 2014-01-28 | 2020-07-14 | 巴克老龄化研究所 | 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物 |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| KR102456088B1 (ko) | 2014-04-04 | 2022-10-19 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| MX2017007637A (es) * | 2014-12-09 | 2017-09-05 | Abbvie Inc | Compuestos inhibidores de bcl-xl y conjugados de anticuerpo-farmaco que los incluyen. |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| JP6936498B2 (ja) * | 2016-04-21 | 2021-09-15 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ | 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用 |
| US20190153107A1 (en) * | 2016-06-08 | 2019-05-23 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
| CN109912655B (zh) * | 2017-12-13 | 2021-12-10 | 上海科技大学 | Alk蛋白降解剂及其抗肿瘤应用 |
| CN114206443B (zh) * | 2019-05-10 | 2024-02-09 | 浙江海正药业股份有限公司 | 芳环或杂芳环类衍生物及其制备方法和用途 |
| CN113509605B (zh) * | 2021-07-14 | 2022-09-20 | 江苏赛腾医疗科技有限公司 | 膜式氧合器 |
| WO2023246924A1 (zh) * | 2022-06-24 | 2023-12-28 | 南京瑞初医药有限公司 | 苯并噻唑化合物及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2332756A1 (fr) | 1975-11-26 | 1977-06-24 | Squibb & Sons Inc | Nouvelles 1, 4-benzoxazin-3(4h)-ones |
| DE19929785A1 (de) | 1999-06-29 | 2001-01-04 | Bayer Ag | Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-Derivate und ihre Verwendung |
| JP2003521543A (ja) | 2000-02-07 | 2003-07-15 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用 |
| BR0112883A (pt) | 2000-08-01 | 2003-06-24 | Ono Pharmaceutical Co | Composto de derivado de 3,4-diidroisoquinolina e um agente farmacêutico compreendendo o mesmo como ingrediente ativo |
| JP2005515158A (ja) * | 2001-05-30 | 2005-05-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Ｂｌｃ−２ファミリータンパク質の小分子アンタゴニスト |
| WO2004004727A1 (en) | 2002-07-03 | 2004-01-15 | Axys Pharmaceuticals, Inc. | 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis |
| CN1856477A (zh) | 2003-09-23 | 2006-11-01 | 默克公司 | 异喹啉钾通道抑制剂 |
| PL2134685T3 (pl) | 2007-04-16 | 2016-02-29 | Abbvie Inc | Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1 |
| US20090039553A1 (en) | 2007-08-10 | 2009-02-12 | 3M Innovative Properties Company | Microstructured surface molding method |
| EP2193127A4 (en) | 2007-09-27 | 2011-09-14 | Inst Medical W & E Hall | BENZOTHIAZOLE COMPOUNDS |
| WO2009105746A2 (en) * | 2008-02-22 | 2009-08-27 | University Of South Florida | Triazoles and processes for producing the same |
| UA108193C2 (uk) | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| RU2525116C2 (ru) * | 2008-12-19 | 2014-08-10 | Дженентек, Инк. | Гетероциклические соединения и способы применения |
| EP2376085B1 (en) | 2008-12-19 | 2014-02-26 | Genentech, Inc. | Compounds and methods of use |
| CN104906100A (zh) | 2009-05-26 | 2015-09-16 | 艾伯维巴哈马有限公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN103987711B (zh) | 2011-10-14 | 2016-08-24 | 艾伯维公司 | 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物 |
| US8940737B2 (en) | 2011-10-14 | 2015-01-27 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| JP6225187B2 (ja) | 2012-08-13 | 2017-11-01 | アッヴィ・インコーポレイテッド | アポトーシス誘発剤 |
-
2012
- 2012-10-11 US US13/649,950 patent/US8940737B2/en active Active
- 2012-10-11 CN CN201280059860.1A patent/CN103958508B/zh active Active
- 2012-11-10 UA UAA201405088A patent/UA112326C2/uk unknown
-
2014
- 2014-04-11 GT GT201400066A patent/GT201400066A/es unknown
- 2014-05-14 CR CR20140226A patent/CR20140226A/es unknown
- 2014-12-03 US US14/559,828 patent/US9266877B2/en active Active
-
2016
- 2016-01-13 US US14/994,824 patent/US9877958B2/en active Active
-
2017
- 2017-12-18 US US15/845,835 patent/US20180221363A1/en not_active Abandoned
-
2019
- 2019-12-18 US US16/719,794 patent/US20200345717A1/en not_active Abandoned
-
2020
- 2020-12-01 US US17/108,719 patent/US20210346369A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20200345717A1 (en) | 2020-11-05 |
| UA112326C2 (uk) | 2016-08-25 |
| GT201400066A (es) | 2015-03-23 |
| US20180221363A1 (en) | 2018-08-09 |
| CN103958508B (zh) | 2019-02-12 |
| US9877958B2 (en) | 2018-01-30 |
| US9266877B2 (en) | 2016-02-23 |
| US20150152097A1 (en) | 2015-06-04 |
| US8940737B2 (en) | 2015-01-27 |
| US20130096121A1 (en) | 2013-04-18 |
| US20160206611A1 (en) | 2016-07-21 |
| CN103958508A (zh) | 2014-07-30 |
| US20210346369A1 (en) | 2021-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20140226A (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes | |
| UY34382A (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes | |
| IL260511B (en) | Prodrugs of fumarates and their use in the treatment of various diseases | |
| IL287315A (en) | Apoptosis-inducing factors for the treatment of cancer and immune and autoimmune diseases | |
| UY34381A (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes | |
| HK1232119A1 (zh) | 用於治療癌症的檢查點抑制劑和治療劑的組合 | |
| ES2546294T7 (es) | Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias | |
| HK1222552A1 (zh) | 索布替羅用於治療髓鞘形成疾病 | |
| CL2015001157A1 (es) | Composiciones y métodos para tratar proteinopatías. | |
| BR112014011009A2 (pt) | inibidor duplo de met e vegf para tratar câncer | |
| HK1221424A1 (zh) | 治療癌症的藥物組合 | |
| BR112014006419A2 (pt) | métodos para tratar um paciente com câncer, kit e artigo | |
| HK1211471A1 (en) | Treating th2-mediated diseases by inhibition of bromodomain- comprising proteins brd7 and brd9 brd7 brd9 th2 | |
| CO6910198A2 (es) | Compuestos y métodos para mejorar las respuestas inmunitarias innatas | |
| BR112015002681A2 (pt) | método para tratar um paciente e kit | |
| EP2958964A4 (en) | TREATMENT OF FREQUENTLY AFFECTED SURFACES TO IMPROVE HYGIENE | |
| UY34078A (es) | Composiciones farmacéuticas y métodos para tratar el cáncer | |
| HK1214301A1 (zh) | 治療 相關疾病的有機組合物 | |
| IL245231A0 (en) | Use of cystamine and its history for the treatment of mitochondrial diseases | |
| ES2664234T8 (es) | Aparato de iluminación y método para reducir la incomodidad del deslumbramiento | |
| EP2686001A4 (en) | USES OF MODIFIED ELR-CXC-MODIFIED G31P CHEMOKINE FOR TREATING CANCER | |
| BR112014015703A2 (pt) | método para tratar uma susceptibilidade ao câncer um um humano | |
| CO7121349A2 (es) | Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek | |
| PL3079684T3 (pl) | Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna | |
| IL243566A0 (en) | igf-1r inhibitors and their use in the treatment of neurodegenerative diseases |